AIA Group Ltd Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AIA Group Ltd boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,600 shares of the biopharmaceutical company’s stock after buying an additional 2,959 shares during the period. AIA Group Ltd’s holdings in Regeneron Pharmaceuticals were worth $9,688,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. D.A. Davidson & CO. boosted its stake in Regeneron Pharmaceuticals by 5.1% in the 3rd quarter. D.A. Davidson & CO. now owns 821 shares of the biopharmaceutical company’s stock worth $863,000 after purchasing an additional 40 shares during the period. Quantbot Technologies LP bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $151,000. Public Sector Pension Investment Board boosted its holdings in Regeneron Pharmaceuticals by 13.0% in the 3rd quarter. Public Sector Pension Investment Board now owns 4,341 shares of the biopharmaceutical company’s stock valued at $4,563,000 after purchasing an additional 500 shares during the period. Hantz Financial Services Inc. grew its position in shares of Regeneron Pharmaceuticals by 87.2% during the 3rd quarter. Hantz Financial Services Inc. now owns 73 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 34 shares in the last quarter. Finally, Captrust Financial Advisors increased its holdings in shares of Regeneron Pharmaceuticals by 3.4% in the third quarter. Captrust Financial Advisors now owns 9,130 shares of the biopharmaceutical company’s stock worth $9,597,000 after purchasing an additional 296 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.2 %

Shares of NASDAQ:REGN opened at $637.36 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a 52-week low of $629.02 and a 52-week high of $1,211.20. The stock has a market capitalization of $69.68 billion, a price-to-earnings ratio of 16.65, a PEG ratio of 2.34 and a beta of 0.27. The stock’s 50-day simple moving average is $683.88 and its two-hundred day simple moving average is $795.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm earned $11.86 EPS. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.55%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Analyst Ratings Changes

Several research firms recently commented on REGN. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Bank of America reiterated an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Robert W. Baird decreased their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. Finally, Citigroup reduced their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.